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tients from both cooperative groups and 10 feasibility
problems occurred in the multicenter setting. Patients re-
ported mixed patterns of responses regarding the different
domains of QoL. Treatment-related effects could be ob-
served. In general, severe limitations in perceived QoL dur-
ing the first 3 years of follow-up were reported. In particu-
lar, levels of emotional strain and fatigue remained high
after the end of active treatment. Women in general re-
ported a lower QoL than men.
CONCLUSION: QoL assessment within international
multicenter trials in HD proved feasible within the two dif-
ferently organized study groups of EORTC and GHSG.
The applied H8/HD8 QoL questionnaire was able to de-
tect distinct patterns of QoL in subgroups of patients.
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OBJECTIVES: Gemcitabine is a new anticancer drug that
has recently been proposed for the treatment of advanced
pancreatic cancer. The therapy with gemcitabine has been
reported to confer a survival advantage in comparison
with fluorouracil. Because gemcitabine is expensive, we
estimated the cost per life-year gained using gemcitabine
for this clinical indication.
METHODS: The clinical material utilized in our analysis
was derived from a randomized clinical trial in which the
survival of patients receiving gemcitabine was compared
with that of patients receiving fluorouracil. To obtain an
estimate of effectiveness, the survival curves published in
the trial were analyzed using the Gompertz methodology.
Gemcitabine acquisition cost was based on wholesale
price in Italy, in the UK and in the US. The overall cost of
treatment is presently being estimated by collecting indi-
vidual data on the use of resources and morbidity costs.
RESULTS: The analysis of the survival curves showed
that the mean survival of patients treated with gemcitab-
ine was 6.29 months, while the corresponding value for
patients receiving standard treatment was 3.20 months
(both values include discounting at an annual rate of
3%). The survival gain for the gemcitabine group was 2.9
months per patient. Our analysis of cost data for these
two treatments is in progress, but preliminary data show
that the incremental cost is less than $20,000 per patient. 
CONCLUSIONS: In pancreatic cancer, gemcitabine de-
termines a survival gain of approximately 3 months. Its
cost-effectiveness profile seems to be within acceptable
values.
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OBJECTIVE: To collect resource utilization and unit costs
in Belgium for treatment of severe neutropenia of five
chemotreated cancer types for which no reimbursement of
prophylactic Neupogen use is available. These cancer types
include multiple myeloma (MM), metastatic breast cancer,
small cell lung cancer, non–small cell lung cancer, and blad-
der cancer. Another goal is to identify factors that may ex-
plain cost variation in treatment of severe neutropenia.
METHODS: Retrospective data collection of bills from
patients treated for severe neutropenia from nine hospital
centers spread all over Belgium over a period of 1 year
(1/96–1/97). Severe neutropenia was defined as a neutro-
penic episode requiring hospitalization. Only direct medi-
cal costs were considered from the perspective of reim-
bursement. Items collected included: hospital stay (duration
and type), diagnostic procedures, drugs, transfusions, in-
terventions; and medical consults.
RESULTS: Seventy-nine patient bills were collected. More
than 75% of the registered neutropenic events occurred dur-
ing first three chemo cycles. Total mean cost (35 Bfr  1
US$) was $4.918 (Med.: $4.529; 95% CI: $4.303–$5.533).
DISCUSSION: Multiple regression analysis demonstrates
that two factors (hospital duration and institution type)
explain 85% of the cost variation. The institution factor
may, however, mask a bias, as all the hematological can-
cers (17%) with their more costly treatment procedures
for neutropenia were treated in university centers. 85%
of treatment cost is composed of only three factors: hos-
pital stay (60%); drug regimen (15%); and lab tests per-
formed (10%). 
CONCLUSION: The treatment cost of neutropenia var-
ies. Its spread is skewed to the right. It is appropriate to
calculate geometric mean cost and to introduce specific
cost estimates per institution type or per cancer type (he-
matological/nonhematological).
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Febrile neutropenia (FN) represents one of the leading
dose-limiting toxicities of cancer chemotherapy. CSFs have
been shown to reduce the incidence of FN in a variety of
settings. Cost-minimization models have established FN
